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Abstract
 
Several newly arising human antibodies are polyreactive, but in normal individuals the majority
of these potentially autodestructive antibodies are removed from the repertoire by receptor editing
or B cell deletion in the bone marrow. To determine what proportion of naturally arising autoanti-
bodies can be silenced by immunoglobulin (Ig) light chain receptor editing, we replaced the
light chains in 12 such antibodies with a panel of representative Ig
 
 
 
 and Ig
 
 
 
 chains. We found
that most naturally arising autoantibodies are readily silenced by light chain exchange. Thus,
receptor editing may account for most autoreactive antibody silencing in humans. Light chain
complementarity determining region (CDR) isoelectric points did not correlate with silencing
activity, but Ig
 
 
 
 genes were more effective than Ig
 
 
 
 genes as silencers. The greater efficacy of
Ig
 
 
 
 chains as silencer of autoreactivity provides a possible explanation for the expansion and altered
configuration of the Ig
 
 
 
 locus in evolution.
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Introduction
 
Antibody genes are assembled by random recombination of
Ig variable (V), diversity (D), and joining (J) gene segments
leading to the production of diverse antibody repertoire
(1). Diversity is essential to ensure that the immune system
can recognize several potential pathogens, but the cost of
producing receptors by random gene recombination is that
many antibodies are self-reactive (2). In mice, the majority
of these potentially self-destructive autoantibodies are re-
moved from the repertoire in the early stages of B cell devel-
opment by receptor editing or deletion, and the few self-
reactive B cells that escape central censorship are rendered
anergic (3–7). Although the extent of autoreactive B cell
deletion and anergy are unknown, it has been estimated
that in the mouse, receptor editing is an important contrib-
utor to the antibody repertoire, accounting for 25–50% of
all antibodies (8–10).
Receptor editing is fundamentally different from deletion
or anergy in that it spares self-reactive B cells by producing
nonself-reactive receptors (3–5). Both Ig heavy (IgH) and
Ig light (IgL) chains can be replaced by editing, but light
chain replacement appears to be the dominant form of re-
ceptor editing (3–5, 11–28).
Receptor editing has been studied primarily in mice carry-
ing transgenes that encode somatically mutated antibodies
derived from autoimmune MRL/lpr (anti-DNA, 3H9) or
immunized (anti-MHC, 3-83) mice (3–5, 11–29). The mo-
lecular basis for silencing DNA-binding by 3H9 IgH chain
is neutralization of positively charged IgH chain comple-
mentarity determining region (CDR) arginine residues by
light chains that have negatively charged CDRs (16, 25,
28). Based on these observations, it was proposed that anti-
DNA editor light chains have low CDR isoelectric points
(pIs) with aspartate residues at key positions (16, 25, 28).
The editor light chains for the anti-MHC antibody 3-83
have not been defined, but 3-83 editing is associated with
increased Ig
 
 
 
 expression, suggesting that Ig
 
 
 
 contributes to
receptor editing (4, 8, 19, 21, 22, 30). Further evidence for
a role of Ig
 
 
 
 in receptor editing in mice comes from the ob-
servation that 47% of all Ig
 
 
 
-expressing B cells carry produc-
tively rearranged Ig
 
 
 
 genes (8). However, not all Ig
 
 
 
 genes
in the mouse serve as editors, and in some cases, Ig
 
 
 
 appears
to increase self-reactivity (9, 12, 14, 26, 27).
The majority of the antibodies produced by early imma-
ture B cells are autoreactive (2), but little is known about
receptor editing of naturally arising autoantibodies (28). To
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examine the IgL chain features that regulate silencing of
naturally arising autoantibodies in humans, we systemati-
cally exchanged the IgL chains cloned from such antibodies
with a collection of 12 selected Ig
 
 
 
 and Ig
 
 
 
 chains. Here,
we report that most of the self-reactive antibodies normally
generated in human bone marrow can be silenced by IgL
chain replacement and that human Ig
 
 
 
 light chains are
more effective silencers than Ig
 
 
 
 chains.
 
Materials and Methods
 
Antibody Production and Purification. 
 
Heavy and light chain
cDNAs were the same as reported previously (2). For antibody
production, 293A human embryonic kidney fibroblasts were
transfected as described previously (2). In brief, cells were cul-
tured in DMEM supplemented with 10% ultra-low IgG FCS
(GIBCO BRL) and cotransfected with IgH and IgL chain–
encoding plasmid DNA by calcium phosphate precipitation.
8–12 h after transfection, cells were washed with serum-free DMEM
and thereafter cultured in DMEM supplemented with 1% Nutri-
doma SP (Roche). Supernatants were collected after 8 d of cul-
ture. Antibodies were purified by binding to protein G–Sepha-
rose™ (Amersham Biosciences) and eluted with 0.1 M glycine
buffer (pH 
 
 
 
 3). Antibody concentrations in tissue culture su-
pernatants and after purification were determined by anti–
human IgG1 ELISA using human monoclonal IgG1 as standard
(Sigma-Aldrich).
 
ELISAs. 
 
ELISAs were performed as described previously
(2). In brief, tissue culture supernatants were adjusted to a starting
antibody concentration of 1 
 
 
 
g/ml for polyreactivity ELISAs and
used at three subsequent 1:4 dilutions in PBS. Specific antigens
were coated on microtiter plates (COSTAR Easywash Polysty-
rene Plates; Corning) at 10 
 
 
 
g/ml for ssDNA, dsDNA, and LPS
(Sigma-Aldrich) or 5 
 
 
 
g/ml for recombinant human insulin
(Fitzgerald). Samples were considered negative if the OD
 
405
 
 did
not exceed a preset threshold value at any of the four dilutions
(OD
 
405
 
: ssDNA, 0.4; dsDNA, 0.42; insulin, 0.5; and LPS, 0.45)
in at least two independent experiments. In all experiments,
ED38 (2, 31) was included as positive control and m-GO13 (2) as
negative control. HEp-2 ELISAs were performed on QUANTA
Lite™ antinuclear antibody (ANA) ELISA plates (INOVA Diag-
nostics) coated with HEp-2 cell lysates. Purified antibodies were
used at a concentration of 25 
 
 
 
g/ml with three subsequent 1:4
dilutions in PBS. The threshold OD
 
405
 
 below which samples
were considered negative was 0.4. Positive and negative controls
included sera from patients and healthy individuals (INOVA Di-
agnostics) as well as ED38 and were included in every experi-
ment. All ELISAs were developed with horseradish peroxidase–
labeled goat anti–human IgG Fc Ab (Jackson ImmunoResearch
Figure 1. Characteristics of se-
lected polyreactive antibodies, Ig 
and Ig  light chains. (A) ELISA
reactivity of antibodies from early
immature B cells with ssDNA,
dsDNA, insulin, and LPS (refer-
ence 2). Positive control anti-
body ED38 (references 2, 31) is
shown as a dashed line. (B) CDR
pIs and CDR3 sequences of the
Ig  and Ig  light chains used for
IgL chain exchange experiments.
*, the V 1-5 gene used in these
experiments has a CDR pI of 8.9
due to a polymorphism in CDR2
(Table S1). (C) Relative repre-
sentation of individual human
V  and V  genes in the repertoire
of expressed human antibodies
(reference 2). V genes are ordered
5  to 3  according to their posi-
tion in the chromosome relative
to the IgL chain constant region
genes. (black bars) V genes selected
for IgL chain exchange experi-
ments. (D) CDR pIs of func-
tional human Ig  (  ) and Ig 
( ) V genes. Arrows indicate V
genes selected for IgL chain ex-
change experiments except for
V 1-5 as indicated (*), for which
a polymorphic version of the
gene with a CDR pI of 8.9 was
used (B). CDR pIs are displayed
on the y axis. 
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Laboratories) and horseradish peroxidase substrate (Bio-Rad Lab-
oratories). OD
 
405
 
 was measured on a microplate reader (Molecu-
lar Devices).
 
Indirect Immunofluorescence Assay (IFA). 
 
IFAs were performed
as described previously (2). In brief, HEp-2 cell coated slides
(Bion Enterprises, Ltd.) were incubated at room temperature
with purified antibodies at 25–150 
 
 
 
g/ml for 30 min, washed in
PBS, and visualized with FITC anti–human Ig by fluorescence
microscopy. Controls included ED38, and positive and negative
sera (Bion Enterprises, Ltd.).
 
Calculation of pIs. 
 
CDR pIs were calculated based on CDR1,
CDR2, and CDR3 amino acid sequences.
 
Statistics. 
 
p-values were calculated by two-tailed Fisher Ex-
act test.
 
Online Supplemental Material.
 
Table S1 shows heavy and light
chain Ig gene repertoire and ELISA reactivity of antibodies from
which individual IgH and IgL chains were derived. Table S2 de-
picts ELISA reactivity with ssDNA, dsDNA, LPS, and insulin of
antibodies expressing IgH chains (ei17, ei62, ei33, and ei102)
from early immature B cells that cannot be silenced by IgL chain
receptor editing. Table S3 shows ELISA reactivity with ssDNA,
dsDNA, LPS, insulin, and HEp-2 and HEp-2 IFA of antibodies
expressing IgH chains (ei95, ei40, ei141, ei69, and ei115) from
early immature B cells that can be silenced by IgL chain receptor
editing. Table S4 depicts ELISA reactivity with ssDNA, dsDNA,
LPS, and insulin of antibodies expressing IgH chains from new
emigrant (ne5, ne77) and mature (m37) B cells that can be si-
lenced by IgL chain receptor editing. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/jem.
20040818/DC1.
 
Results
 
Many naturally arising autoantibodies react with several
different self-antigens including DNA and are referred to as
polyreactive. These antibodies make up a majority of all
newly arising antibodies in humans. However, few mature
B cells produce polyreactive antibodies because they are re-
moved from the repertoire during B cell development in
the bone marrow, primarily in the transition between the
early immature and the immature B cell stage. This stage in
B cell development corresponds to the stage associated with
receptor editing and autoreactive B cell deletion.
 
Silencing Polyreactive Antibodies. 
 
To determine whether
naturally arising human autoreactive antibodies can be si-
lenced by IgL chain replacement, we coexpressed IgH
chains from nine polyreactive early immature B cell anti-
bodies with a panel of different IgL chains (2). The polyre-
active antibodies selected were representative of such anti-
bodies in that they showed varying affinities for ssDNA,
dsDNA, insulin, and LPS (Fig. 1 A and reference 2). Three
highly polyreactive heavy chains (ei17, ei33, and ei62), rep-
resenting 10% of the initial antibody repertoire, were se-
lected, whereas the other six (ei40, ei69, ei95, ei102, ei115,
Figure 2. Refractory polyreac-
tive antibodies. Data show ELISA
reactivity on ssDNA, dsDNA, Insulin,
and LPS for ei17, ei62, ei33, and
ei102 IgH chains combined with
different IgL chains. The original
IgL chain is represented in red, those
that failed to silence in black, and
the positive control antibody ED38
(references 2, 31) as a dashed line.
The horizontal line in each graph
shows the threshold for positive re-
activity. (n) The number of different
IgL chains tested for each IgH chain. 
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and ei141), representing 45% of the initial repertoire, were
less polyreactive (2). Each of the nine heavy chains was
paired with each of six Ig
 
 
 
 or six Ig
 
 
 
 chains that had been
cloned from B cells from the same healthy donors (Fig. 1 B,
Table S1, available at http://www.jem.org/cgi/content/
full/jem.20040818/DC1, and reference 2). These IgL
chains were selected based on frequency of V gene usage
and the range of IgL chain CDR pIs (Fig. 1, B–D, and ref-
erence 2). The IgL chain panel includes 10 of the most fre-
quently used human Ig
 
 
 
 and Ig
 
 
 
 V genes as well as V
 
 
 
1-
33, with a CDR pI of 3.1, and V
 
 
 
7-46, with a CDR pI of
8.7 (Fig. 1, B–D). Together, the selected V regions of the
IgL chains cover 63% of the V
 
 
 
 and 61% of the V
 
 
 
 genes
found in the normal human antibody repertoire (2, 32, 33)
and their CDR pIs range from 3.1 to 10.9 (Fig. 1, B–D).
Nearly all combinations of heavy and light chains (129
out of 144) were efficiently produced in transfected tissue
culture cells (
 
 
 
1 
 
 
 
g/ml of supernatant), suggesting that the
majority of IgH chains expressed by human B cells are
compatible with a wide range of light chains (Tables S1–
S4, available at http://www.jem.org/cgi/content/full/jem.
20040818/DC1). We found that four of the nine IgH
chains (ei17, ei33, ei62, and ei102) could not be silenced by
any of the 
 
 
 
- or 
 
 
 
-IgL chains tested (Fig. 2 and Table S2).
Three of these “nonsilenceable” IgH chains (ei17, ei62, and
ei33) were cloned from rare early immature B cells express-
ing highly reactive antibodies (10% of all polyreactive anti-
bodies expressed in early immature B cells; reference 2). In
addition, IgH ei33 was originally cloned from an unusual B
cell that expressed two IgL chains, one Ig
 
 
 
 and one Ig
 
 
 
(Figs. 1 A and 2). The reactivity of these heavy chains was
barely modulated by any of the IgL chains, including V
 
 
 
1-
33 and V
 
 
 
1-44 with CDR pIs of 3.1 and 3.9, respectively.
The fourth IgH chain in the nonsilenceable group (ei102)
was different from the other three in that the original anti-
body showed modest levels of polyreactivity and almost all
of the light chains tested increased polyreactivity when
compared with the original (Fig. 2). The remaining five
polyreactive antibodies from immature B cells showed the
low to intermediate levels of autoreactivity displayed by
45% of all antibodies expressed in early immature B cells
(ei95, ei40, ei141, ei69, and ei115; reference 2). These anti-
bodies were readily silenced by light chain exchange (Fig. 3
and Table S3). However, each heavy chain displayed a dif-
ferent pattern of silencing by IgL chains, and some IgL
chains even enhanced the reactivity of some heavy chains
Figure 3. Responsive polyreactive antibodies. Data show ELISA reactivity on ssDNA, dsDNA, Insulin, and LPS for ei95, ei40, ei141, ei69, and ei115
IgH chains combined with different IgL chains. The original IgL chain is represented in red, those that failed to silence in black, those that silenced reactivity
in green, and the positive control antibody ED38 (references 2, 31) as a dashed line. The horizontal line in each graph shows the threshold for positive
reactivity. For each IgH chain, the number of effective editors of polyreactivity as a proportion of the number of light chains tested is indicated (bottom). 
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(Fig. 3). In one unusual case, the original light chain might
have been responsible for polyreactivity, ei95, because ex-
change with any Ig
 
 
 
 or Ig
 
 
 
 silenced the reactivity of this
antibody (Fig. 3). We conclude that highly reactive autoan-
tibodies found in 10% of all early immature B cells are diffi-
cult to silence, whereas most of the remaining polyreactive
antibodies representing 
 
 
 
45% of the repertoire can readily
be silenced by light chain exchange.
 
Silencing ANAs. 
 
Polyreactive antibodies are efficiently
removed from the repertoire between the early immature
and the immature stage of B cell development (2). How-
ever, several B cells that pass this first checkpoint still ex-
press autoreactive antibodies as measured by HEp-2 cell
ELISA and indirect immunofluorescence, which are stan-
dard clinical tests for autoantibodies (2). To determine
whether light chains that silenced polyreactivity also alter
this other form of autoreactivity, we tested four of the si-
lenceable heavy chains (ei40, ei141, ei69, and ei115) in
HEp-2 ELISAs (Fig. 3). With one exception, all polyreac-
tive antibodies were also reactive in the HEp-2 cell ELISA
(Fig. 4 and Table S3), but silencing polyreactivity did not
always correlate with silencing for HEp-2 reactivity (Fig. 4
and Table S3). For example, 9 out of 12 of the IgL chains
tested silenced polyreactivity for IgH chain ei40 but only 2
of these completely abolished autoreactivity as measured in
the HEp-2 cell ELISA and IFA (Figs. 3 and 4 and Table
S3). In contrast, 3 out of 10 IgL chains tested silenced
polyreactivity for IgH chain ei69 and all 3 also abolished
HEp-2 cell reactivity (Fig. 4 and Table S3). However, light
chains that failed to silence HEp-2 cell reactivity modulated
the nature of the autoreactivity as measured by indirect im-
munofluorescence (Fig. 4 B and Table S3). Polyreactive
antibodies from early immature B cells frequently show
nuclear and cytoplasmic staining by immunofluorescence
(Fig. 4 B and reference 2). Pairing with nonnative IgL
chains that silenced polyreactivity typically altered the pat-
tern of HEp-2 cellular staining (Fig. 4 B). We conclude
that loss of polyreactivity by light chain replacement does
not always correlate with silencing HEp-2 cell reactivity.
This difference in silencing between polyreactivity and
HEp-2 reactivity may explain why large numbers of HEp-2
cell–reactive B cells remain until later stages of B cell de-
velopment even after polyreactive antibodies are removed
from the repertoire (2). Finally, our findings are consistent
with the suggestion that light chains contribute to ANA
autospecificity (11).
 
Peripheral Polyreactive Antibodies. 
 
Although the major-
ity of polyreactive antibodies are counter-selected between
the early immature to immature B cell stage in the bone
marrow, a small number of antibodies showing low levels
of polyreactivity can be detected in the periphery (2). To
determine if these antibodies could be silenced by light
chain replacement, we coexpressed each of three such IgH
chains (ne5, ne77, and m37) with our panel of Ig
 
 
 
 and
Ig
 
 
 
 chains and tested the antibodies for polyreactivity (Fig.
5). We found that all three of these heavy chains were
readily silenced by IgL chain replacement (Fig. 5 and Table
S4). We conclude that, in humans, the few peripheral B
cells expressing antibodies with low levels of polyreactivity
could have been edited in the bone marrow, but were not.
Thus, editing is either incomplete or unnecessary for anti-
bodies with low levels of polyreactivity.
 
pI and Light Chain Isotype. 
 
In the mouse, there is a di-
rect correlation between the ability of a light chain to serve
as an editor of anti-DNA antibodies and low CDR pIs (25,
28). Similar rules do not appear to apply to silencing of
Figure 4. HEp-2 cell ELISA
and indirect immunofluores-
cence. Data show HEp-2 cell
ELISA reactivity and immunoflu-
orescence  for four silenceable
heavy chains ei40, ei141, ei69,
and ei115 (top) combined with
different IgL chains. (A) ELISAs.
Graphs, symbols, and IgL chain
representation as in Fig 3. (B) In-
direct immunofluorescence. Orig-
inal polyreactive antibodies (top)
and the same IgH chain paired
with IgL chains that did not
abolish HEp-2 reactivity, but
with the exception of IgH chain
ei69/Ig 1-44 (bottom). The edi-
tor light chain is indicated (bottom
left of each micrograph). For
each IgH chain, the number of
effective editors of HEp-2 cell
reactivity as a proportion of the
number of light chains tested is
indicated (bottom). 
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naturally arising polyreactive antibodies with anti-DNA re-
activity in humans (Fig. 6). We found no correlation be-
tween Ig
 
 
 
 or Ig
 
 
 
 CDR pIs and silencing (Fig. 6). For ex-
ample, V
 
 
 
1-33 with the lowest CDR pI (3.1) was the only
Ig
 
 
 
 tested that could not silence DNA binding by IgH
chain ei40. In contrast, the same V
 
 
 
1-33 was the only light
chain that was able to silence DNA binding by IgH chain
ei115. In addition, V
 
 
 
3-15 with a CDR pI of 10.9 had the
same overall ability to silence DNA binding by nine differ-
ent heavy chains as V
 
 
 
1-33 with a CDR pI of 3.1. These
observations are consistent with our previous finding that
there was no correlation between IgL chain V gene usage
and antibody reactivity (Fig. 6, A and B, and reference 2).
Although IgL chain CDR pI did not correlate with silenc-
ing, comparison of Ig
 
 
 
 and Ig
 
 
 
 genes showed that Ig
 
 
 
s are
more effective than Ig
 
 
 
s in antibody silencing (Fig. 6 A,
P 
 
  
 
0.01). Individually, all Ig V
 
 
 
 genes with the exception
of V
 
 
 
3-1 were equal to or better silencers than Ig
 
 
 
 V
genes (Fig. 6 A). To determine whether light chain isotype
might influence self-reactivity in vivo, we compared the
frequency of Ig
 
 
 
 and Ig
 
 
 
 in self-reactive and nonself-reac-
tive antibodies found in immature bone marrow B cells
and peripheral new emigrant B cells in healthy human do-
nors (2). We found that newly produced self-reactive anti-
bodies were more likely to include Ig
 
 
 
 than Ig
 
 
 
 light
chains (Fig. 6 C, P 
 
  
 
0.001). Although Ig
 
 
 
 genes normally
recombine before Ig
 
 
 
 and, therefore, are unlikely to edit
Ig
 
 
 
 antibodies, Ig  occasionally silenced Ig  antibodies in
vitro. For example, two Ig s and V 1-33 silenced ei115, a
clone originally expressing an Ig  chain. We conclude
that, in humans, Ig  light chains are better potential editors
of naturally arising polyreactive antibodies than Ig  light
chains and that the ability of an IgL chain to silence polyre-
Figure 5. Polyreactive antibodies cloned from peripheral blood B cells.
Data show ELISA reactivity on ssDNA, dsDNA, Insulin, and LPS for
ne5, ne77, and ne37 IgH chains combined with different IgL chains.
Graphs, symbols, and IgL chain representation as in Fig. 3. For each IgH
chain, the number of effective editors of polyreactivity as a proportion of
the number of light chains tested is indicated (bottom).
Figure 6. Characteristics of
editor light chains. (A) IgL chains
that edit individual silenceable IgH
chains. IgH chains are indicated
(top). Editor IgL chains (left,
Ig ; right, Ig ) are shown in
black bars above the line, and
noneditor IgL chains in white
bars are shown below the line.
(B) The percentage of all tested
IgH chains that could be silenced
by a particular Ig  (  ) or Ig 
( ) light chain plotted on the y
axis versus CDR pI of the IgL
chain on the x axis. (C) The per-
centage of Ig  (n   42) or Ig 
(n     83) bearing antibodies
cloned from immature and new-
emigrant B cells from two healthy
donors that were self-reactive
( ) or nonself-reactive ( ) (ref-
erence 2).Wardemann et al. 197
activity, including DNA-binding, does not correlate with
CDR pI.
Discussion
In humans, random gene V, D, and J segment usage
leads to the expression of several autoantibodies in early
immature B cells (2). These autoantibodies fall into two
groups, polyreactive antibodies and HEp-2 cell binding
ANAs. The vast majority of polyreactive antibodies are re-
moved from the repertoire in the transition between the
early immature and the immature stage of B cell develop-
ment. Few polyreactive antibody-producing B cells escape
to the periphery and those that do show only low levels of
reactivity (2). In contrast, B cells producing HEp-2 cell–
reactive ANAs are only partially removed in the early im-
mature to immature B cell transition, and additional selec-
tion occurs between the new emigrant and the mature B
cell stage in the periphery (2).
Experiments with transgenic mice have established that
newly arising self-reactive antibodies are removed by two
mechanisms, receptor editing and deletion, and that self-
reactive B cells that escape central censorship are rendered
anergic (3–7). The mechanism that mediates editing is be-
lieved to involve trapping nascent B cells expressing au-
toantibodies in the early immature stage of B cell develop-
ment where persistent V(D)J recombination leads to IgV
gene replacement. Those B cells that succeed in silencing
their self-reactive antibodies by gene replacement are re-
leased from the early immature B cell stage and complete B
cell development. Several lines of experimental evidence
support this kinetic model for receptor editing. For exam-
ple, there is expansion of the early immature B cell com-
partment and increased RAG expression in mice carrying
transgenic antibodies that are difficult to edit (5, 30, 34),
and in the absence of RAG expression, self-reactive B cells
are deleted (35). Conversely, self-reactive B cells that are
artificially kept alive with Bcl-2 display increased receptor
editing (18, 21, 22). Finally, direct measurements show de-
layed B cell development under conditions of receptor ed-
iting (9, 10).
Despite the important contribution of editing to the an-
tibody repertoire, little is known about the ability of light
chains to edit naturally arising self-antibodies. The proper-
ties of editor light chains have been examined systemati-
cally only for the 3H9 anti-DNA antibody, which was de-
rived from a somatically mutated IgG found in the spleen
of autoimmune MRL/lpr mice (36). DNA binding by 3H9
is dependent on arginine residues, and only a limited num-
ber of Ig  chains with low CDR pIs that neutralize these
charges are effective editors (25, 28). The number of light
chains that edit the 3H9 IgH chain increases when it is re-
verted to a lower affinity unmutated germline form. The
germline version of 3H9 has reactivity with phosphati-
dylserine in addition to DNA and, therefore, resembles
some of the polyreactive antibodies reported here. Con-
versely, fewer light chains can edit when IgH chain argi-
nines are added to increase DNA affinity (25, 28). Thus, it
was initially surprising to find no apparent correlation be-
tween IgL chain CDR pIs and anti-DNA silencing activity
in naturally arising human antibodies. However, the mech-
anism of DNA binding by naturally arising polyreactive an-
tibodies is unknown, and may differ from pathogenic anti-
DNA antibodies such as 3H9 that are clonally expanded in
autoimmune prone mice (36). Long and positively charged
IgH CDR3s have been associated with polyreactivity (2,
28, 37). Indeed, 20% of naturally arising human polyreac-
tive antibodies have no positively charged residues in IgH
chain CDR3, 27% had a single positive charge, and 53%
have two or more positive charges (2). This represents a
significant increase in positively charged IgH chain CDR3s
in polyreactive antibodies when compared with nonreac-
tive antibodies, but positively charged CDR3s are neither
essential for nor diagnostic of polyreactivity in naturally
arising antibodies (2).
Polyreactive antibodies frequently show ANA reactivity
in clinical ELISA assays on HEp-2 cell lysates. Although
polyreactivity is efficiently silenced in the bone marrow,
the number of B cells that express autoreactive antibodies
as measured by HEp-2 cell ELISA only drops from 76 to
43% between the early immature and immature B cell
stages (2). However, the HEp-2 cell–reactive antibodies
expressed by immature B cells show preferential loss of nu-
clear reactivity when compared with those expressed by
early immature B cells (2). This is consistent with our ob-
servation that polyreactive antibodies silenced by IgL chain
exchange frequently retain HEp-2 cell reactivity, but the
pattern of staining is altered. Thus, the light chain in these
antibodies determines the type of autoreactivity. Preferen-
tial loss of polyreactivity by light chain replacement during
receptor editing could explain why polyreactivity is effi-
ciently silenced while 43% of immature B cells continue to
express HEp-2 cell–reactive ANAs (2).
Light chain exchange silenced most heavy chains with
intermediate levels of polyreactivity typical of the majority
of early immature polyreactive antibodies, but a subgroup
of heavy chains could not be silenced. Three out of the
four IgH chains that were refractory to silencing by light
chain exchange showed long and charged CDR3s (ei17,
ei62, and ei102). Two of these were initially highly polyre-
active (ei17 and ei62), but the third (ei102) was unusual in
that it started off with low-level polyreactivity; all of the
IgL chains tested in swapping experiments increased the
level of reactivity. This antibody (ei102) was initially an Ig 
antibody and, therefore, may have been the end product of
receptor editing that could not be further silenced. The
fourth nonsilenceable heavy chain (ei33) did not have a
long CDR3, but was highly charged and showed the most
basic CDR pI of all IgH chains tested (10.1). In addition,
IgH chain ei33 was cloned from a cell expressing both Ig 
and Ig , a feature associated with extensive receptor editing
in the mouse (26). Antibodies with long and charged IgH
chain CDR3s represent 10% of the self-reactive antibodies
cloned from early immature B cells in normal humans, butHuman Antibody Receptor Editing 198
they are rarely found in the periphery (2, 38, 39). If light
chain editing is also ineffective against such IgH chains in
vivo, then B cells that carry such IgH chains must undergo
either heavy chain receptor editing or deletion (13). Con-
sistent with this idea, it has been estimated that 5% of hu-
man B cells carry heavy chains that result from receptor
editing (40). All of the five remaining antibodies with in-
termediate levels of polyreactivity representing the majority
of polyreactive antibodies found in early immature B cells
were silenced. Thus, the majority of naturally arising hu-
man self-reactive B cells need not be deleted but can be si-
lenced by IgL chain replacement.
A small number of polyreactive antibodies escape the
early immature to immature checkpoint in the bone mar-
row and can be found in the periphery, and cells producing
these antibodies may even be positively selected because
they produce “natural antibodies” (2). These antibodies
typically show low levels of self-reactivity, and all such an-
tibodies tested were readily silenced by IgL chain exchange.
Therefore, editing could have repaired these antibodies,
but did not. B cells that express such antibodies (4% of all
mature B cells in normal humans) may be anergic. Alterna-
tively, they may be precursors of marginal zone or B1 type
cells, which are B cell subpopulations that appear to be en-
riched in low affinity polyreactive antibodies (41).
In humans, 40% of all antibodies carry Ig  light chains,
whereas in mice, only 5% are Ig . There are only three V 
genes in the mouse, and the locus is not permissive for re-
ceptor editing by nested recombination. In contrast, there
are 30 functional V  genes in humans, and the Ig  locus is
permissive for receptor editing, but it may not have dele-
tional elements similar to those found in the Ig  locus that
limit Ig  receptor editing (42, 43). In humans, B cells ex-
pressing Ig  invariably have recombined Ig , but Ig -
expressing cells only occasionally carry recombined Ig ,
suggesting an ordered model for light chain gene recom-
bination where Ig  precedes Ig  (33, 44, 45). Thus, au-
toantibodies bearing Ig  and unable to find an Ig  editor
would eventually delete the Ig  locus by recombination
but could still be silenced by Ig  recombination. Finding
that in humans, Ig  is more effective in silencing of natu-
rally arising autoantibodies than Ig  was unexpected, and
the structural basis for this difference is not readily apparent,
but the observation is consistent with the finding that Ig -
expressing immature and new emigrant B cells are less
likely to be self-reactive than Ig -expressing cells (Fig. 6
C). Given the several self-reactive antibodies produced in
early immature B cells, strong selective pressure for editor
IgL chains would be expected. Efficient silencing by Ig 
provides a potential rationale for the expanded role of the
Ig  locus in man.
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